Literature DB >> 15958061

Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells.

Ryuji Ikeda1, Xiao-Fang Che, Tatsuya Yamaguchi, Mina Ushiyama, Chun-Lei Zheng, Hiroshi Okumura, Yasuo Takeda, Yoshihiko Shibayama, Kazuo Nakamura, Hei-Cheul Jeung, Tatsuhiko Furukawa, Tomoyuki Sumizawa, Misako Haraguchi, Shin-ichi Akiyama, Katsushi Yamada.   

Abstract

A major impediment to cancer treatment is the development of resistance by the tumor. P-glycoprotein (P-gp) and multidrug resistance protein 1 (MRP1) are involved in multidrug resistance. In addition to the extrusion of chemotherapeutic agents through these transporters, it has been reported that there are differences in the intracellular distribution of chemotherapeutic agents between drug resistant cells and sensitive cells. Cepharanthine is a plant alkaloid that effectively reverses resistance to anticancer agents. It has been previously shown that cepharanthine is an effective agent for the reversal of resistance in P-gp-overexpressing cells. Cepharanthine has also been reported to have numerous pharmacological effects besides the inhibition of P-gp. It has also been found that cepharanthine enhanced sensitivity to doxorubicin (ADM) and vincristine (VCR), and enhanced apoptosis induced by ADM and VCR of P-gp negative K562 cells. Cepharanthine changed the distribution of ADM from cytoplasmic vesicles to nucleoplasm in K562 cells by inhibiting the acidification of cytoplasmic organelles. Cepharanthine in combination with ADM should be useful for treating patients with tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958061     DOI: 10.1111/j.1349-7006.2005.00057.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  8 in total

1.  Pharmacological blockade of cholesterol trafficking by cepharanthine in endothelial cells suppresses angiogenesis and tumor growth.

Authors:  Junfang Lyu; Eun Ju Yang; Sarah A Head; Nana Ai; Baoyuan Zhang; Changjie Wu; Ruo-Jing Li; Yifan Liu; Chen Yang; Yongjun Dang; Ho Jeong Kwon; Wei Ge; Jun O Liu; Joong Sup Shim
Journal:  Cancer Lett       Date:  2017-09-18       Impact factor: 8.679

2.  Secondary Metabolites from Plants Inhibiting ABC Transporters and Reversing Resistance of Cancer Cells and Microbes to Cytotoxic and Antimicrobial Agents.

Authors:  Michael Wink; Mohamed L Ashour; Mahmoud Zaki El-Readi
Journal:  Front Microbiol       Date:  2012-04-23       Impact factor: 5.640

Review 3.  P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review.

Authors:  Hossam M Abdallah; Ahmed M Al-Abd; Riham Salah El-Dine; Ali M El-Halawany
Journal:  J Adv Res       Date:  2014-12-01       Impact factor: 10.479

4.  [Solasonine-induced Apoptosis in Lung Cancer Cell Line H446 and Its Mechanism].

Authors:  Wensi Huang; Ying Wang; Haitao Zhu; Yingying Wu; Xiaodong Xie; Dongqing Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-07

Review 5.  Natural Products as Alternative Choices for P-Glycoprotein (P-gp) Inhibition.

Authors:  Saikat Dewanjee; Tarun K Dua; Niloy Bhattacharjee; Anup Das; Moumita Gangopadhyay; Ritu Khanra; Swarnalata Joardar; Muhammad Riaz; Vincenzo De Feo; Muhammad Zia-Ul-Haq
Journal:  Molecules       Date:  2017-05-25       Impact factor: 4.411

6.  Determination of cepharanthine in rat plasma by LC-MS/MS and its application to a pharmacokinetic study.

Authors:  Yingbin Deng; Weijun Wu; Sunzhi Ye; Wei Wang; Zhiyi Wang
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

Review 7.  Cepharanthine: An update of its mode of action, pharmacological properties and medical applications.

Authors:  Christian Bailly
Journal:  Phytomedicine       Date:  2019-05-10       Impact factor: 5.340

8.  Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)-mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals.

Authors:  Pengjun Zhou; Rong Zhang; Ying Wang; Dandan Xu; Li Zhang; Jinhong Qin; Guifeng Su; Yue Feng; Hongce Chen; Siyuan You; Wen Rui; Huizhong Liu; Suhong Chen; Hongyuan Chen; Yifei Wang
Journal:  Oncotarget       Date:  2017-11-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.